Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nonocclusive Mesenteric Ischemia in Cardiogenic Shock: Mechanisms of Splanchnic Hypoperfusion and Strategies for Early Detection.

Cardiology in review·2026

Same author

Transplant Allograft Markers of Rejection for Heart, Liver, and Kidney Transplantation: A Review.

Cardiology in review·2026

Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026

Same author

Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey.

Liver international : official journal of the International Association for the Study of the Liver·2026

Same author

Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities.

Annals of hepatology·2026

Same author

A Retrospective Analysis of Glucagon-like Peptide-1 Receptor Agonists on Bowel Preparation Efficacy in Colonoscopies.

American journal of therapeutics·2026

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Cardiovascular diseases and the liver.

Ilan S Weisberg¹, Ira M Jacobson

¹Division of Gastroenterology and Hepatology, Weill Cornell Medical Center, New York Presbyterian Hospital, 1305 York Avenue, 4th Floor, New York, NY 10021, USA.

Clinics in Liver Disease

|November 30, 2010

Summary

The liver

Area of Science:

Cardiovascular Medicine
Hepatology
Hepatic Blood Flow Dynamics

Background:

The liver possesses a unique dual blood supply from the portal vein and hepatic artery, conferring resistance to minor circulatory issues.
Hepatic complications associated with common cardiovascular disorders are prevalent in clinical practice.
Understanding liver circulation is crucial for diagnosing and managing cardiovascular-related liver diseases.

Purpose of the Study:

To review the pathophysiology of hepatic blood flow, considering both macro- and microcirculation.
To provide a detailed appraisal of ischemic hepatitis and congestive hepatopathy.
To discuss other hepatic conditions resulting from impaired cardiovascular function.

Main Methods:

Review of existing literature on liver physiology and cardiovascular pathology.

Related Experiment Videos

Last Updated: Jun 6, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Analysis of the interplay between systemic circulation and hepatic perfusion.

Synthesis of information on specific hepatic conditions linked to cardiovascular disease.

Main Results:

The liver's dual blood supply offers some protection, but cardiovascular disorders frequently impact liver function.
Ischemic hepatitis and congestive hepatopathy are significant hepatic manifestations of cardiac dysfunction.
Various other less common hepatic conditions can arise due to impaired cardiovascular health.

Conclusions:

Cardiovascular disorders commonly lead to hepatic manifestations requiring clinical attention.
Impaired hepatic blood flow due to cardiovascular disease results in conditions like ischemic hepatitis and congestive hepatopathy.
A comprehensive understanding of hepatic circulation and cardiovascular interactions is essential for effective patient management.